Elacestrant - OmicsDI

Show results for

Unknown (33)
Genomics (12)
Transcriptomics (7)
Metabolomics (1)
Proteomics (1)

Organisms

Homo sapiens (9)
Alphavirus (1)
Anemia (1)
Archaea (1)
Bacteria (1)
Betaherpesvirinae (1)
Borrelia (1)
Clostridium perfringens (1)
Cowpox virus (1)
Cytomegalovirus (1)
Dengue virus (1)
EFO:0001352 (1)
Hepatitis B virus (1)
Human alphaherpesvirus 1 (1)
Human betaherpesvirus 5 (1)
Human immunodeficiency virus (1)
Influenza A virus (1)
Influenza C virus (1)
Japanese encephalitis virus group (1)
Kamptonema sp. (1)
Listeria monocytogenes (1)
Mammarenavirus (1)
Miscanthus x giganteus (1)
Mycobacterium tuberculosis (1)
Rattus (1)
Sarbecovirus (1)
Severe acute respiratory syndrome coronavirus 2 (1)
Staphylococcus aureus (1)
Streptococcus pneumoniae (1)
Viruses (1)

Organisms

Homo sapiens (8)

Repository

ENA (10)
geo (9)
MetaboLights (1)
pride (1)

Tissue

Cell culture (1)

Technology Type

Mass spectrometry assay (1)
Mass Spectrometry (1)
Shotgun proteomics (1)

Instrument Platform

Liquid Chromatography MS - alternating - reverse-phase (1)

Metabolite Name

4-{[(4-Fluorophenyl)sulfonyl]amino}butanoic acid (1)
N-[2-(4-Benzyl-1-piperazinyl)-2-(3-pyridinyl)ethyl]-N¡ä-mesitylethanediamide (1)
5-Carboxybenzofuroxan (1)
(8S,11R,13R,14S,17S)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one (1)
PG(16:1(9Z)/0:0) (1)
CE(18:3(6Z,9Z,12Z)) (1)
2-[(2E,6E,10E,14E,18Z,22E,26E,30E,34E,38E,42E)-3,7,11,15,19,23,27,31,35,39,43,47-Dodecamethyl-2,6,10,14,18,22,26,30,34,38,42,46-octatetracontadodecaenyl]-5,6-dimethoxy-3-methylbenzo-1,4-quinone (1)
1-[4-(2-bromobenzoyl)-1H-pyrrol-2-yl]-2,2,2-trichloro-1-ethanone (1)
Docetaxal (1)
2-Chloro-5-nitropyrimidine (1)
Balofloxacin (1)
8-Bromo-2¡ä-deoxyadenosine (1)
[Similar to: 6-(3-chloro-4-methylphenyl)-1,3,5-triazine-2,4-diamine (1)
4-[3-(3,5-Ditert-butylphenyl)-3-oxoprop-1-enyl]benzoic acid (1)
Methyl 3-(2-furoylamino)-5-[(1-isopropyl-4-piperidinyl)amino]-1-(3-methylbutyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate (1)
1-Oxa-3-azaspiro[4.5]decan-2-one, 4-hydroxy-4-methyl-3-(2,2,6,6-tetramethyl-4-piperidyl)- (1)
Intoplicine (1)
PA(17:2(9Z,12Z)/0:0) (1)
(6E)-6-({(E)-2-[(2-Hydroxyphenyl)amino]vinyl}imino)-2,4-cyclohexadien-1-one (1)
(3S,4aS,8aS)-N-tert-butyl-2-{(2R,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutyl}decahydroisoquinoline-3-carboxamide (1)
Silane, ethenylethoxydiphenyl- (1)
2-{1-(4-Ethoxybenzyl)-4-[(4-isopropyl-1,3-thiazol-2-yl)methyl]piperazin-2-yl}ethanol (1)
Hexahydrosiladifenidol (1)
N-[2-(Dibutylamino)ethyl]-6-[(4-methyl-1-piperidinyl)sulfonyl]-2-(3-pyridinyl)-4-quinolinecarboxamide (1)
Allitridin (1)
5-Bromo-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide (1)
5-(4-Bromo-benzylidene)-pyrimidine-2,4,6-trione (1)
PA(13:0/20:1(11Z)) (1)
(4-Anilino-1-naphthyl){bis[4-(dimethylamino)phenyl]}methanol (1)
LMGP06020030 (1)

First Public Date

2022 (4)
2026 (3)
2023 (3)

Release Date

2025 (11)
2023 (6)
2022 (5)
2026 (3)
2024 (3)
2021 (2)
2020 (2)
2019 (1)

Lab affiliation

The Institute of Cancer Research Breast Cancer Now (1)

Publication date

2026 (4)
2023 (4)
2022 (3)

Tags

xref:PubMed:41193244 (3)
xref:PubMed:38102750 (1)

Previous page
1 / 6
You're on page 1
page 2
page 3
page 4
page 5
page 6
Next page

Sort by:

Relevance

Page size

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen receptor positive endocrine-resistant and fulvestrant-resistant breast cancer

Human breast cancer cell lines were cultured in phenol red-free RPMI1640 medium supplemented with 10% fetal bovine serum and 1nM E2. All cell lines were banked in multiple aliquots to reduce the risk of phenotypic drift and identity confirmed using STR. Cells were routinely screened for mycoplasma c...

ORGANISM(S): Homo sapiens (Human)

2023-03-10 | PXD031377 | Pride

Elacestrant: First Approval.

Not available

S-EPMC10667141 | biostudies-literature

RNAseq: Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen- receptor positive endocrine-resistant and fulvestrant-resistant breast cancer

PRJNA786919 | ENA

RNAseq: Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen- receptor positive endocrine-resistant and fulvestrant-resistant breast cancer

We carried out a comparative study of the orally bioavailable investigational SERD elacestrant, versus fulvestrant, in models of endocrine sensitive and resistant BC harbouring varying genetic backgrounds. Both drugs showed comparable effects on tumour growth of ER+ patient-derived xenograft models ...

ORGANISM(S): Homo sapiens

2022-08-01 | GSE190384 | GEO

ChIP-seq: Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen- receptor positive endocrine-resistant and fulvestrant-resistant breast cancer

PRJNA786918 | ENA

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.

Not available

S-EPMC10300156 | biostudies-literature

ChIP-seq: Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen- receptor positive endocrine-resistant and fulvestrant-resistant breast cancer

ORGANISM(S): Homo sapiens

2022-08-01 | GSE190385 | GEO

Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date.

Not available